This forms a key part of ADC Bio’s construction of a new bioconjugation facility at its site in Deeside, North Wales, UK for the commercial production of antibody drug conjugates in response to global customer demand.
Antibody drug conjugates are a class of emerging biotherapeutics that require a bespoke infrastructure to ensure strict compliance with the highest global regulatory standards.
WHP, the multi-disciplinary engineering company, was awarded the £5m contract in December 2017, and the new facility - which includes support areas for washing, depyrogenation, thawing and buffer preparation - sees drug manufacturing in a stringently controlled environment, operated under cGMP regulations. This eliminates any risks during antibody modification and conjugation that could support the development of environmentally-borne microbial contaminants.
WHP’s scope of work covered the design and build, including test and validation of a state-of-the-art containment manufacturing cleanroom within an existing 6,500m2 high tech facility, along with new quality control and process development laboratories.
Charlie Johnson, CEO at ADC Bio, said: “We are building a best in class facility to the highest possible global standards. We awarded the contract to WHP on the back of its relevant industry experience and reputation for delivering cost-effective, single source cleanroom design and build packages.
“It’s a facility we are extremely proud of that will help our customers develop vital new medicines for patients globally.”
WHP’s project manager, Chris Douglas, said: “The new cleanroom meets ADC Bio’s need to expand operations at Deeside beyond R&D to include safe, secure and highly efficient manufacturing capabilities.
“This latest project reflects growing success in delivering high quality cleanroom technologies across the pharmaceutical sector, providing customers with expertise, knowledge and one-stop-shop solutions.”
